To test or not to test this should be patient’s decision – Advocates for Universal DPD/DPYD Testing
Advocates for Universal DPD/DPYD Testing shared a post by Ken Surprenanton, Advocate at DPD/DPYD, on LinkedIn, adding:
”To test or not to test: this should be PATIENT’S decision, not the doctor’s. In 2024, with the scientific knowledge of pharmacogenomics like the FDA Table of Pharmacogenomic Associations (as just one of many examples) who would want to be treated with fluoropyrimidine chemotherapy without a DPYD test? Informed patients would choose to be tested.”
Quoting Ken Surprenant’s post:
”A desperate defense of the status quo in the use of fluoropyrimidines. We, our ‘interest group’ will respond and point out that it is ultimately the patient who should decide to opt out, not the oncologist.”
Source: Advocates for Universal DPD/DPYD Testing/LinkedIn and Ken Surprenant/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023